Avilar Therapeutics Revenue and Competitors

Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degrader therapeutics that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC-mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA.